Frontiers in Cardiovascular Medicine (Sep 2021)

Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment

  • Bo Zhu,
  • Siu-Lung Chan,
  • Jack Li,
  • Kathryn Li,
  • Hao Wu,
  • Kui Cui,
  • Hong Chen

DOI
https://doi.org/10.3389/fcvm.2021.742382
Journal volume & issue
Vol. 8

Abstract

Read online

There has been a rise in the prevalence of non-alcohol fatty liver disease (NAFLD) due to the popularity of western diets and sedentary lifestyles. One quarter of NAFLD patients is diagnosed with non-alcoholic steatohepatitis (NASH), with histological evidence not only of fat accumulation in hepatocytes but also of liver cell injury and death due to long-term inflammation. Severe NASH patients have increased risks of cirrhosis and liver cancer. In this review, we discuss the pathogenesis and current methods of diagnosis for NASH, and current status of drug development for this life-threatening liver disease.

Keywords